Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias

Background Vincristine sulfate liposome injection (VSLI; Marqibo®) is an encapsulated preparation of standard vincristine in sphingomyelin/cholesterol liposomes. Clinical trials in adults have demonstrated safety, tolerability, and activity, leading to Food and Drug Administration (FDA) approval for...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Pediatric blood & cancer Ročník 63; číslo 6; s. 997 - 1005
Hlavní autoři:	Shah, Nirali N., Merchant, Melinda S., Cole, Diane E., Jayaprakash, Nalini, Bernstein, Donna, Delbrook, Cindy, Richards, Kelly, Widemann, Brigitte C., Wayne, Alan S.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Blackwell Publishing Ltd 01.06.2016 Wiley Subscription Services, Inc
Témata:	acute lymphoblastic leukemia Adolescent Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - pharmacokinetics Chemotherapy Child Child, Preschool Female Hematology Humans Leukemia Liposomes Male Marqibo Maximum Tolerated Dose Neoplasms - drug therapy Oncology pediatric Pediatrics phase I Registries Vincristine - administration & dosage Vincristine - adverse effects Vincristine - pharmacokinetics Young Adult Marqibo phase I acute lymphoblastic leukemia pediatric
ISSN:	1545-5009, 1545-5017, 1545-5017
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!